ENDRA Life Sciences (NDRA) Equity Average (2017 - 2021)
Historic Equity Average for ENDRA Life Sciences (NDRA) over the last 5 years, with Q3 2021 value amounting to $14.1 million.
- ENDRA Life Sciences' Equity Average rose 55275.66% to $14.1 million in Q3 2021 from the same period last year, while for Sep 2021 it was $14.1 million, marking a year-over-year increase of 55275.66%. This contributed to the annual value of $6.0 million for FY2020, which is 836.7% up from last year.
- Latest data reveals that ENDRA Life Sciences reported Equity Average of $14.1 million as of Q3 2021, which was up 55275.66% from $16.4 million recorded in Q2 2021.
- ENDRA Life Sciences' Equity Average's 5-year high stood at $16.4 million during Q2 2021, with a 5-year trough of -$1.1 million in Q1 2017.
- Over the past 5 years, ENDRA Life Sciences' median Equity Average value was $3.2 million (recorded in 2017), while the average stood at $5.0 million.
- In the last 5 years, ENDRA Life Sciences' Equity Average crashed by 9007.96% in 2018 and then skyrocketed by 83863.49% in 2021.
- ENDRA Life Sciences' Equity Average (Quarter) stood at $6.2 million in 2017, then crashed by 53.46% to $2.9 million in 2018, then rose by 6.44% to $3.1 million in 2019, then soared by 70.43% to $5.3 million in 2020, then skyrocketed by 167.95% to $14.1 million in 2021.
- Its Equity Average was $14.1 million in Q3 2021, compared to $16.4 million in Q2 2021 and $12.5 million in Q1 2021.